Freenome Inc. Common stock (FRNM)
Stock · NASDAQ · Health Care
$11.73as of 10/16/2026
Price chart
Active signals
FRNM Signal Track Record
How signals performed across all stocks →What FRNM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 14 | +0.4% | 50% | September 3, 2026 |
| Volume Spike | 11 | +2.5% | 73% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 5 | +1.1% | 80% | June 23, 2026 |
| Any 20-session window (baseline) | +0.8% | 65% |
Computed by MarketWall from daily closing prices since March 31, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FRNM
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as t…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 375
Fundamentals
- 1-day range
- $11.67$12.73
- Market cap
- $1.17B
- P/E (trailing)
- —
- P/E (forward)
- -4.93
- EPS (trailing)
- $-0.07
- Dividend yield
- —
- Beta
- 0.01
- Avg. volume
- 849.1K
Forecasts
5 analyst ratings
Freenome Inc. Common stock Competitors
Chosen by industry and closest market cap.
- FRNMFreenome Inc. Common stock$11.75▼ 4.35%Market cap $1.17BP/E —$9.97$17.5
- TRUPTrupanion Inc. Common Stock$28.12▲ 0.93%Market cap $1.23BP/E 53.48$21.16$46.98
- LMRILumexa Imaging Holdings Inc. Common Stock$10.78▲ 0.00%Market cap $1.10BP/E —$6.45$19.45
- PSNLPersonalis Inc. Common Stock$15.65▼ 1.76%Market cap $1.39BP/E —$4.96$18.89
- CSTLCastle Biosciences Inc. Common Stock$31.96▼ 5.44%Market cap $930.84MP/E —$17.72$44.28
- FTREFortrea Holdings Inc. Common Stock$22.49▼ 1.12%Market cap $1.68BP/E —$8.55$23.51
- FLGTFulgent Genetics Inc. Common Stock$19.81▼ 7.17%Market cap $510.41MP/E —$13.46$31.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FRNM Freenome Inc. Common stock | $1.17B | — | $11.75 | ▼ 4.35% | $9.97$17.5 |
| TRUP Trupanion Inc. Common Stock | $1.23B | 53.48 | $28.12 | ▲ 0.93% | $21.16$46.98 |
| LMRI Lumexa Imaging Holdings Inc. Common Stock | $1.10B | — | $10.78 | ▲ 0.00% | $6.45$19.45 |
| PSNL Personalis Inc. Common Stock | $1.39B | — | $15.65 | ▼ 1.76% | $4.96$18.89 |
| CSTL Castle Biosciences Inc. Common Stock | $930.84M | — | $31.96 | ▼ 5.44% | $17.72$44.28 |
| FTRE Fortrea Holdings Inc. Common Stock | $1.68B | — | $22.49 | ▼ 1.12% | $8.55$23.51 |
| FLGT Fulgent Genetics Inc. Common Stock | $510.41M | — | $19.81 | ▼ 7.17% | $13.46$31.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing CompetitionSeekingAlpha · 9/22/2026
Insider Activity
Insider Actions →- Elliott Aaron Matthew · September 2, 2026 · Tax Withholding71.9K @ $15.25
- Kenneth Song · July 20, 2026 · Conversion30.0K
- Perceptive Capital Solutions Holdings · July 20, 2026 · Conversion2.07M
- Mark C. McKenna · July 20, 2026 · Conversion30.0K
- Michael Seth Altman · July 20, 2026 · Conversion2.07M
- Adam Leo Stone · July 20, 2026 · Conversion2.07M
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant337.0K @ $10
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant4.92M @ $10
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant367.4K
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant908.1K
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant553.7K
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant971.0K
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant6.56M
- PERCEPTIVE ADVISORS LLC · July 20, 2026 · Grant5.50M @ $10
- Harlan Waksal · July 20, 2026 · Conversion30.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Freenome highlights CRC screening market potential
Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.
Freenome highlights CRC screening market potential. Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.